H
Haystack MRD™ by Quest Diagnostics is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after cancer treatment. Based on more than 20 years of clinical development and technology from pioneers in cancer genomics at Johns Hopkins University, Haystack MRD's purpose-built, high-precision science delivers novel insights that can help inform treatment decision-making.
Investor insights
Funding rounds participated in
$56M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2021
Funding rounds raised
Total raised
$56M
from 2 investors over 1 rounds
H
Haystack MRD™ by Quest Diagnostics® raised $56M on December 16, 2022
Investors: Catalio Capital Management and + 2 Other investors